Bleomycin

Overview

Bleomycin (Blenoxane®) is an antineoplastic antibiotic used infrequently in dogs and cats for the management of selected neoplasms. It may be administered systemically or by intralesional injection, with intralesional therapy showing particular promise for localized tumors.

In veterinary oncology, bleomycin has been used in the treatment of lymphomas, oral squamous cell carcinomas, teratomas, nonfunctional thyroid tumors, and certain locally invasive oral tumors. However, evidence suggests limited single-agent activity in canine lymphoma, and it is often incorporated into combination or specialized treatment protocols.

Mechanism of Action (MOA): Bleomycin binds to DNA and forms a complex with ferrous iron, acting as an electron acceptor that facilitates free radical formation. This interaction results in DNA strand breaks and inhibition of DNA synthesis, ultimately leading to apoptosis of neoplastic cells.

Indications

In dogs and cats, bleomycin is used for selected neoplastic conditions, typically under the supervision of a veterinary oncologist. It may be administered systemically as part of chemotherapy protocols or locally via intralesional injection for certain tumors.

• Lymphoma: Has been used in canine and feline lymphoma protocols; however, single-agent activity in canine lymphoma appears to be limited and it is generally not relied upon as monotherapy.
• Oral squamous cell carcinoma: Used as part of treatment strategies for oral tumors in dogs and cats.
• Teratomas and nonfunctional thyroid tumors: Reported use in selected cases where chemotherapy is indicated.
• Localized tumors (intralesional therapy): Intralesional bleomycin, with or without electropermeabilization, may be beneficial for certain accessible, localized tumors in dogs and cats.
• Acanthomatous ameloblastoma (dogs): Intralesional administration has been successfully used in dogs with this locally aggressive oral tumor.

Dosage (Reference)

Dog

In dogs, bleomycin is administered parenterally and should only be used under the supervision of a veterinary oncology specialist due to its narrow therapeutic index and potential for serious toxicity.

Cat

In cats, bleomycin dosing follows the same protocol as in dogs. Extreme caution is required due to the risk of cumulative pulmonary toxicity and other systemic adverse effects.

Warnings & Precautions

Bleomycin is a cytotoxic antineoplastic agent with a low therapeutic index and the potential for serious, life-threatening toxicity. It should only be administered in facilities capable of providing intensive monitoring and managing chemotherapy-related complications.

• Low therapeutic index: Extreme caution is required due to the narrow safety margin. Dosage calculations must be verified carefully before each administration.
• Cumulative pulmonary toxicity: Risk of pneumonitis and pulmonary fibrosis increases with cumulative dosing; total lifetime dose should not exceed recommended limits.
• Preexisting pulmonary disease: Use cautiously in patients with underlying lung disease or prior pulmonary adverse effects from therapy.
• Renal impairment: Dosage reduction may be necessary in patients with significant renal dysfunction, as renal excretion contributes to drug elimination.
• Previous hypersensitivity reactions: Contraindicated in patients with known hypersensitivity to bleomycin.
• Pregnancy: Bleomycin may be teratogenic; use only when potential benefits outweigh risks and with informed owner consent.
• Hazardous drug classification: Classified as a hazardous drug by NIOSH; appropriate personal protective equipment (PPE) must be used during preparation, administration, and disposal.
• Specialist supervision: Due to potential severe toxicities, treatment should be directed by or in consultation with a veterinary oncologist.

Drug Interactions

Bleomycin-associated drug interactions in dogs and cats are primarily related to increased pulmonary, hematologic, renal, or immunologic toxicity. Careful case evaluation and enhanced monitoring are required when bleomycin is used concurrently with the following agents.

• General anesthetics: Prior exposure to bleomycin may sensitize lung tissue to oxygen, even at commonly used inspired oxygen concentrations. There is an increased risk of postoperative pulmonary deterioration and fibrosis; use perioperative oxygen cautiously.
• Prior or concomitant chemotherapy, radiation therapy, or immunosuppressants: May increase the risk of hematologic suppression, mucosal injury, and pulmonary toxicity.
• Granulocyte colony-stimulating factors (e.g., filgrastim): May increase the risk of pulmonary toxicity when used concurrently.
• Nephrotoxic agents (e.g., aminoglycosides, amphotericin B, cisplatin, iohexol): Concurrent administration may increase the risk of renal toxicity.
• Vaccines (live or inactivated): Antineoplastic therapy may reduce vaccine efficacy and increase the risk of adverse vaccine reactions; vaccination timing should be carefully considered.

Side Effects & Overdose

Side Effects

Adverse effects of bleomycin in dogs and cats fall into two main categories: acute reactions and delayed toxicities. Severity is often dose-related and may be associated with cumulative exposure.

• Acute reactions: Fever, anorexia, mild vomiting, and hypersensitivity reactions, including anaphylaxis, may occur shortly after administration.
• Dermatologic effects (delayed): Erythema, hyperpigmentation, rash, and skin tenderness have been reported with continued therapy.
• Stomatitis: Oral mucosal inflammation may develop during treatment.
• Pulmonary toxicity: Pneumonitis and pulmonary fibrosis are the most serious delayed toxicities and may be fatal. Early changes may include interstitial edema and progressive respiratory compromise.
• Hematologic effects: Unlike many other chemotherapeutic agents, significant myelosuppression is uncommon; however, thrombocytopenia, leukopenia, and mild decreases in hemoglobin may occur.
• Renal and hepatic toxicity: Increases in renal or hepatic parameters are possible and warrant monitoring.
• Gastrointestinal effects: At commonly used doses in dogs (0.5 IU/kg), adverse effects were reported as infrequent and primarily gastrointestinal.

Overdose

Bleomycin has no known antidote. Because of its narrow therapeutic index, overdose can result in severe and potentially irreversible toxicity, particularly affecting the lungs.

• Enhanced pulmonary toxicity: Increased risk of pneumonitis and pulmonary fibrosis with excessive cumulative dosing.
• Severe systemic toxicity: May include intensified dermatologic, mucosal, renal, or hematologic adverse effects.
• Management: Immediate discontinuation of therapy and aggressive supportive care are required. Close monitoring of respiratory function, renal parameters, and hematologic status is essential.
• Prevention: Careful verification of dosage calculations and strict tracking of total cumulative dose are critical to avoid overdose.

Key Notes

Practical clinical considerations to optimize the safe and effective use of bleomycin in dogs and cats:

• Body surface area calculations: Cumulative dose limits are expressed in mg/m²; accurate conversion from body weight to body surface area is essential when tracking lifetime exposure.
• Baseline diagnostics: Thoracic radiographs and complete blood count/serum chemistry profiles are recommended prior to initiating therapy to establish reference values.
• Ongoing respiratory monitoring: Periodic thoracic imaging and careful lung auscultation during treatment help detect early pulmonary changes before clinical deterioration occurs.
• Renal excretion awareness: Because a substantial portion of the drug is eliminated renally, hydration status and renal function should be considered throughout treatment.
• Handling precautions for owners: On treatment days and for several days afterward, owners should wear disposable gloves when handling urine, feces, vomit, or litter, and seal waste before disposal.
• Storage considerations: Store unopened vials refrigerated (2–8°C). After reconstitution with appropriate diluent, solutions are stable for 24 hours.
• Administration compatibility: Compatible with 0.9% sodium chloride for dilution; avoid dilution in dextrose 5% in water due to reduced potency.